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Abstract 
The stromal interaction molecule (STIM)‑calcium release‑activated calcium channel protein (ORAI) and inositol 
1,4,5‑trisphosphate receptors (IP3Rs) play pivotal roles in the modulation of Ca
2+‑regulated pathways from gene 
transcription to cell apoptosis by driving calcium‑dependent signaling processes. Increasing evidence has implicated 
the dysregulation of STIM–ORAI and IP3Rs in tumorigenesis and tumor progression. By controlling the activities, struc‑
ture, and/or expression levels of these Ca2+‑transporting proteins, malignant cancer cells can hijack them to drive 
essential biological functions for tumor development. However, the molecular mechanisms underlying the participa‑
tion of STIM–ORAI and IP3Rs in the biological behavior of cancer remain elusive. In this review, we summarize recent 
advances regarding STIM–ORAI and IP3Rs and discuss how they promote cell proliferation, apoptosis evasion, and 
cell migration through temporal and spatial rearrangements in certain types of malignant cells. An understanding of 
the essential roles of STIM–ORAI and IP3Rs may provide new pharmacologic targets that achieve a better therapeutic 
effect by inhibiting their actions in key intracellular signaling pathways.
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Background
Calcium signals are widespread and rigorously regulate 
the majority of fundamentally important physiologic pro-
cesses ranging from cell proliferation to cell apoptosis [1]. 
The precise and tightly controlled intracellular calcium 
ion concentration depends on finely tuned modulation 
by various calcium-transporting processes, including 
Ca2+ channels, pumps, and receptors [2]. These Ca2+-
transporting molecules strictly regulate the transient or 
sustained waves, spikes, or oscillations of Ca2+ signaling 
in different cellular compartments and microdomains 
to maintain a delicate balance between feeding into 
the cytoplasm and releasing from internal Ca2+ stores 
[3]. Any perturbation and disorder of the delicate Ca2+ 
homeostasis may lead to long-ranging consequences. 
Therefore, it is not surprising that any derangement of 
Ca2+ channels and/or receptors will contribute to the 
establishment of many life-threatening diseases, such as 
cardiopathy [4], heart failure [5], neurodegenerative dis-
eases [6], and cancer [7]. Remarkably, the altered expres-
sion or activity of these Ca2+ channels or receptors is 
characterized by the features of specific cancer subtypes, 
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of which the most important is the protein complex con-
sisting of the stromal interaction molecule (STIM), cal-
cium release-activated calcium channel protein (ORAI), 
and inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs). 
STIM–ORAI is able to sense and respond to intracellu-
lar Ca2+ microenvironmental changes that occur during 
cancer development. This complex primarily mediates 
the Ca2+ influx, with STIM serving as the endoplasmic 
reticulum (ER) Ca2+ sensor and ORAI as the Ca2+-selec-
tive entry channel. Furthermore, the roles of IP3Rs are 
also discussed. There is emerging evidence that IP3Rs, 
which regulate the Ca2+ flux from the ER into the cyto-
sol and mitochondria, play crucial roles in the apoptotic 
pathway; additionally, IP3Rs have been implicated in cel-
lular senescence [3]. The last decade in clinical oncol-
ogy has been noteworthy because of advances in our 
understanding of the derangement of Ca2+ channels/
transporters that are thought to be responsible for the 
development of cancers [8]. Although enormous explora-
tions have been performed, the molecular mechanisms 
by which these derangements affect tumorigenesis and 
tumor progression are far from being fully understood. 
In this review, we discuss recent progress in understand-
ing the roles of STIM–ORAI and IP3Rs, with a focus on 
exploring the mechanism underlying the hijacking of the 
Ca2+-transporting molecules STIM-ORAI and IP3Rs by 
malignant cancer cells that leads to tumor onset, growth, 
and metastasis. The concomitant interaction between 
STIM–ORAI and IP3Rs is also discussed. Understand-
ing the molecular basis and pathologic transformations 
of Ca2+-transporting molecules in cancer cells will offer 
an opportunity for pharmacologic modulation and thera-
peutic intervention.
The structure and function of the STIM and ORAI 
protein families
External stimulation leads to an increase in cytoplasmic 
Ca2+ from either the entry of extracellular Ca2+ across 
the plasma membrane or the release of Ca2+ from inter-
nal calcium stores in the ER and sarcoplasmic reticulum 
(SR) [9]. Both of these functions involve the permeable 
Ca2+ channels that are located on the plasma membrane. 
Upon the stimulation, extracellular Ca2+ can enter the 
cytoplasm through Ca2+ channel transport. Moreover, 
the plasma membrane is responsible for refilling the 
internal Ca2+ stores when they are depleted. The primary 
Ca2+ entry pathway is store-operated Ca2+ entry (SOCE), 
which includes two key components: a sensitive sensor 
of calcium store depletion (STIM) and an effective chan-
nel that can facilitate calcium entry into the cell (ORAI) 
[10–12].
STIM, which is predominantly located in the ER, 
was identified using an RNA interference screen in 
Drosophila S2 cells; then, two mammalian orthologs 
(STIM1 and STIM2) were found [13]. Both STIM1 and 
STIM2 act as sensors of Ca2+ store levels in the ER and 
control calcium refilling by forming connections with 
ORAI [14]. STIM1 contains an ER luminal N-terminus 
and a cytosolic C-terminus. The ER luminal portion 
consists of a canonical Ca2+-binding EF-hand (a con-
ventional helix-loop-helix EF motif ), a hidden EF hand, 
and a sterile α-motif (SAM) domain. The cytosolic strand 
includes three putative coiled-coil (CC1, CC2, and CC3) 
regions, calcium release-activated calcium (CRAC) 
modulatory domain (CAD) or a STIM-ORAI-activating 
region (SOAR), serine or proline-rich segments, and 
lysine-rich regions [15]. The low Ca2+-binding affinity of 
EF-SAM perfectly matches the detailed alteration of the 
Ca2+ concentration and enables the ER sensor protein to 
respond to changes in the Ca2+ concentration in ER. The 
Ca2+ depletion in the ER leads to the dissociation of Ca2+ 
from the EF hand, thereby destabilizing the entire EF-
SAM entity. The CC regions and the serine/proline-rich 
region promote the oligomerization of STIM, thereby 
enabling its redistribution into multiple punctae and its 
localization at ER-plasma membrane junctions. The CC 
domain has been proven to control the exposure and oli-
gomerization of the SOAR [16]. The structure of STIM2 
is similar to that of STIM1; however, STIM1 is widely 
expressed at both the cell surface and the ER, whereas 
STIM2 is expressed only in the intracellular space. A 
growing number of studies have indicated that STIM2 is 
a potent inhibitor and a feedback regulator of STIM1 via 
preventing it from forming an aggregate to stabilize basal 
concentrations of Ca2+ in the cytosol and ER [17]. Thus, 
STIM2 is regarded as a critical regulator of basal Ca2+ 
levels in the human signaling proteome, whereas STIM1 
seems to be more involved in the Ca2+ entry associated 
with more pronounced depletion [18, 19].
The ORAI gene encodes a family consisting of three 
proteins (ORAI1, ORAI2, and ORAI3). Each of these 
proteins consists of 4 TM-spanning segments and 3 cyto-
solic strands, which include the N-terminus, the second 
loop con-necting TM2 and TM3, and the C-terminus 
[20]. The ORAI1 C-terminus forms the cytosolic exten-
sion, and the C-terminal putative CC domain is impor-
tant for binding to the SOAR/CAD domain of STIM1. By 
binding to the intracellular C-terminus, STIM1 recruits 
ORAI to the puncta in the plasma membrane.
The primary intracellular hysiologic functions of 
STIM and ORAI are straightforward (Fig.  1a). STIM 
detects the decrease in Ca2+ stores in the ER and moves 
within the ER to ER-plasma membrane junctions. Then, 
STIM recruits ORAI to the ER-plasma membrane junc-
tions, where the two proteins form a close contact. The 
formation of the active STIM–ORAI complex at the 
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conformational gate of the SOCE channel allows Ca2+ 
entry [21].
The structure and function of the IP3 receptor 
family
The IP3R is the most ubiquitous intracellular Ca2+ chan-
nel, and its isoforms (IP3R1, IP3R2, and IP3R3) have been 
identified in vertebrates [22]. The majority of cell types 
express more than one isoform but have a predominant 
one. The three IP3R isoforms have distinct but overlap-
ping expression patterns. IP3R1 is expressed in neuronal 
cells, IP3R2 is expressed in liver and muscle cells, and 
IP3R3 is expressed in most cultured cell types [23]. The 
general domain structure of IP3Rs (which exist as tetram-
ers) has been determined; IP3Rs contain a binding site for 
IP3 in the N-terminal region, the channel domain, and 
the determinants for tetramer formation in the C-termi-
nus [24, 25].
IP3Rs predominantly reside in the ER. IP3 is pro-
duced by phospholipase C and binds to IP3Rs to induce 
calcium release from the ER upon cell activation by 
endogenous or exogenous hormones, growth factors, or 
Fig. 1 Disrupted dynamic equilibrium of stromal interaction molecule 1 (STIM1)‑calcium release‑activated calcium channel protein 1 (ORAI1) and 
inositol 1,4,5‑trisphosphate receptor (IP3R)‑mediated Ca
2+ signaling in tumor biology. a In normal cells, STIM1 exists as a single‑transmembrane 
protein in the endoplasmic reticulum (ER). The STIM1 canonical Ca2+‑binding EF‑hand (a conventional helix‑loop‑helix EF motif ) can sensitively 
detect the depletion of ER luminal Ca2+, leading to STIM1 oligomerization and interactions with the C‑terminus of ORAI1. The STIM1–ORAI1 com‑
plex controls the opening of the Store‑operated Ca2+ entry (SOCE) channel ORAI1, thereby allowing Ca2+ entry. The increased Ca2+ in the ER can 
enter into the mitochondria via IP3Rs, leading to mitochondrial Ca
2+ overload and indirectly causing apoptosis. The mitochondrial outer membrane 
permeabilization (MOMP) is considered a critical step during the point‑of‑no‑return apoptosis in the mitochondria. b In prostate cancer cells, an 
increase in the level of the endogenous ORAI3 protein causes the association of ORAI3 with ORAI1 to form a heteromultimeric channel that can 
alter the ORAI3‑ORAI1 ratio. These functions represent an oncogenic switch that promotes prostate cancer cell proliferation and confers apoptosis 
resistance. c STIM1–ORAI1‑mediated Ca2+ signaling accelerates tumor cell migration through controlling focal adhesion (FA) turnover and actomyo‑
sin contractility. The STIM1–ORAI1‑mediated Ca2+ influx regulates actomyosin formation and increases its contractile force. STIM1–ORAI1 induces 
the Ca2+ influx and promotes the cleavage of FA proteins. The red represents all of the factors involved in resistance to apoptosis, and the blue 
represents all of the factors that promote apoptosis. d Bcl‑2 is a representative anti‑apoptotic protein that interacts with IP3R via its N‑terminal BH4 
domain. Then, Bcl‑2 inhibits the Ca2+ flux into the mitochondria, leading to mitochondrial Ca2+ deficiency and preventing cancer cell apoptosis. The 
deficient Ca2+ can break MOMP and finally prevent cancer cell apoptosis
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neurotransmitters. Notably, IP3-induced Ca2+ release 
is typically regulated by the Ca2+ concentration in the 
cytosol and ER. Furthermore, the activities of IP3Rs are 
biphasically regulated by cytosolic Ca2+. The concen-
tration–response relationship is a typical bell-shaped 
curve, indicating that the IP3-mediated Ca2+ release is 
potentiated at a low Ca2+ concentration and inhibited 
at a higher concentration [26]. The Ca2+ storage in the 
lumen of the ER also regulates IP3Rs, which can prevent 
excessive ER depletion at low levels of store filling [27]. 
IP3R-mediated Ca2+ elevation regulates fundamental cel-
lular functions, such as fertilization, cell cycle entry, cell 
division, metabolism, and transcription [28]. An impor-
tant function of IP3Rs is to decide the cell fate by control-
ling the mitochondrial Ca2+ elevation and mitochondrial 
metabolism. Cell survival or apoptosis is encoded in the 
frequency and amplitude of Ca2+ oscillations mediated 
by IP3Rs and decoded by different Ca2+-sensitive kinases 
or phosphatases that in turn regulate the target proteins. 
When IP3Rs transport appropriate amounts of Ca2+ from 
the ER to the mitochondria, they catalyze the conversa-
tion of pyruvate to acetyl-coenzyme A (CoA) to produce 
adenosine triphosphate (ATP) and nicotinamide adenine 
dinucleotide 2′-phosphate (NADPH). The insufficient 
transport of Ca2+ to the mitochondria induces cellular 
autophagy. Conversely, when activated IP3Rs excessively 
transport Ca2+ from the ER to the mitochondria, the 
mitochondrial Ca2+ is overloaded, which induces a dis-
sipation of the mitochondrial potential, the opening of 
the permeability transition pore, and the release of pro-
apoptotic factors such as cytochrome c [29]; this process 
ultimately triggers cell apoptosis. Therefore, IP3Rs play 
pivotal roles in the apoptotic process via controlling the 
cellular response to apoptotic signals and conferring 
oncogenic features to the cell [30].
The emerging roles of STIM and ORAI 
in tumorigenesis and tumor progression
STIM and ORAI have been found to be abundantly 
expressed in human cancer tissues and multiple tumor 
cell lines. Abnormal spatial and temporal changes in 
these two proteins have been found to be involved in 
many aspects of tumorigenesis, including cancer cell pro-
liferation, migration, and apoptosis resistance.
STIM and ORAI are overexpressed in tumors
Increasing evidence has shown that STIM and ORAI 
are overexpressed in many types of malignant tumors, 
including breast cancer [31], glioblastoma [32], prostate 
cancer [33], hepatocellular carcinoma [34], esophageal 
squamous cell carcinoma (ESCC) [35], and clear cell 
renal cell carcinoma (ccRCC) [36] (Table 1). An investiga-
tion of 24 patients with cervical cancer found that 71 % 
of the patients showed increased expression of STIM1 
in primary cervical cancer tissues compared with non-
cancerous tissues. Abnormal overexpression of STIM1 
contributed to large tumor sizes and low 5-year survival 
rates. A similar association between STIM expression 
and tumor growth was also demonstrated in the study 
by Yang et al. [34]. The authors found that highly invasive 
CC-LM3 hepatocytes overexpressed STIM1 at a level 
approximately eightfold higher than normal LO2 hepat-
ocytes in  vitro. A study of 295 breast cancer patients 
obtained a similar result [37]. The survival of breast can-
cer patients with high STIM1 mRNA levels in tumors was 
significantly reduced compared with the control group. 
Additionally, STIM1 could also be used as a predictive 
marker for metastatic potential in patients with hepato-
cellular carcinoma [38]. The high expression of ORAI1 
also indicated a poor prognosis and depressed recur-
rence-free survival. In line with these findings, Zhu et al. 
[35] demonstrated that malignant ESCC tissues displayed 
an ectopic overexpression of ORAI1 compared with 
neighboring non-tumorous esophageal tissues. A similar 
result for ORAI3 in breast cancer cell lines was reported 
by Faouzi et al. [39], who showed that the expression of 
the ORAI3 mRNA was increased in breast cancer tissues 
from the majority (76.9  %) of patients compared with 
healthy control tissues. Increased expression of ORAI3 
in tumor tissues from 60 patients presenting non-small 
cell lung adenocarcinoma was also noted by Ay et al. [40]. 
Additionally, Schmidt et al. [41] showed that the expres-
sion levels of STIM and ORAI were significantly higher 
in cisplatin-resistant ovarian carcinoma cells than in cis-
platin-sensitive cells (Table 1). These results provide evi-
dence supporting an association between STIM–ORAI 
expression and poor outcomes in patients with malignant 
cells.
STIM and ORAI: pivotal roles in cancer development
The functions of STIM and ORAI in certain types of 
cancer have fascinated many investigators. The use of 
pharmacologic interference and small interfering RNA 
(siRNA)-mediated gene knockdown approaches to 
down-regulate STIM and ORAI at both the mRNA and 
protein levels inhibits tumor cell proliferation, promotes 
cell apoptosis, and reduces tumor size. These results 
revealed that STIM and ORAI promoted tumorigen-
esis and tumor progression through the following key 
events: elevated proliferation, enhanced migration, and 
increased resistance to apoptosis.
A study of STIM1 indicated that the gene locus encod-
ing STIM1 on chromosome 11p15 was deleted in human 
rhabdomyosarcoma and rhabdoid tumor cell lines [42]. 
Ectopic overexpression of STIM1 in  vitro could induce 
morphologic changes in rhabdomyosarcoma cells and 
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ultimately lead to cell death. Therefore, STIM was a sus-
pected tumor suppressor. However, Gueguinou et al. [43] 
demonstrated that knockdown of STIM1 did not inhibit 
the migration of breast cancer cells. Moreover, Zhu et al. 
[35] showed that there was no significant difference 
between tumor tissues and normal tissues from patients 
with ESCC. These results implied that STIM1 might play 
a nonessential role in cancer metastatic processes. These 
contradictory findings imply that the features and expres-
sion of STIM vary in different cancer tissues and stages.
Compared with STIM, the role of ORAI in tumorigen-
esis may be more explicit. The dysregulation of ORAI is 
affected by the activation of proto-oncogenes or the inac-
tivation of tumor suppressors. Recently, compelling evi-
dence has suggested that ORAI3 is closely related with 
c-Myc, which is a key proto-oncogene and is enhanced 
in most human cancers [43]. In this study, ORAI3 down-
regulation specifically reduced the expression and activ-
ity of c-Myc via the mitogen-activated protein kinase 
(MAPK) pathway, leading to breast cancer cell arrest in 
the G1 phase. Ay et al. [40] found that high expression of 
ORAI3 promoted non-small cell lung adenocarcinoma 
cell proliferation via the phosphoinositide 3-OH kinase 
(PI3K)/Akt signaling pathway, which was constitutively 
activated in lung cancer cells and was central to cell pro-
liferation and survival. Schmidt et  al. [41] also demon-
strated that ORAI overexpression induced the activity of 
the oncoprotein Akt, which contributed to therapy resist-
ance in ovarian carcinoma cells.
Any structural remodeling and functional changes of 
ORAI3 may trigger a switch to a more aggressive cell 
phenotype. Dubois et  al. [44] showed that enhanced 
ORAI3 expression favored heteromerization with ORAI1 
to form a novel channel in in  vitro models; the remod-
eled ORAI1–ORAI3 complex might serve as the onco-
genic switch in prostate cancer (Fig.  1b). Additionally, 
the authors found that the relative expression level of the 
ORAI3 protein in cancer tissues was obviously higher 
than the level in noncancerous tissues. Overexpressed 
ORAI3 was shown to encode SOCE in a subset of breast 
Table 1 Roles of  the stromal interaction molecule (STIM)-calcium release-activated calcium channel protein (ORAI) 
and inositol 1,4,5-trisphosphate receptors (IP3Rs) in tumor invasion and metastasis
Channel Cell type(s) Mechanism and function References
STIM‑ORAI Human breast cancer MDR‑MB‑231 and MCF‑10A cells Regulates focal adhesion (FA) turnover and increases tumor 
cell migration
[31]
Human glioblastoma multiforme (GBM) U251‑MG,  
SNB19, U87, and LN229 cells
Regulates GBM cell invasiveness and increases tumor 
metastasis
[32]
Regulates FA turnover and epithelial‑to‑mesenchymal transi‑
tion
[57]
Clear cell renal cell carcinoma (RCC) Regulates migration and proliferation; increases RCC devel‑
opment
[36]
Human colorectal cancer (CRC) Associated with tumor size, lymph node metastasis, and 
serum levels of carcinoembryonic antigen; promotes CRC 
migration; remolds Ca2+ signal and channel features
[48]
Pancreatic adenocarcinoma Panc1 cells Protects tumor against apoptosis [49]
Human melanoma SK‑Mel‑2 and SK‑Mel‑24 cells Promotes melanoma cells proliferation and migration [50]
ORAI Human prostate epithelial cell line DU145 cells Alters the molecular components of ORAI; increases 
ORAI1:ORAI3 ratio; and is associated with negative prog‑
nosis
[9]
Human esophageal squamous cell carcinoma  
KYSE‑150, ‑190, ‑30, ‑510, and ‑790 cells
Regulates cell proliferation, migration, and invasion; pro‑
motes tumor growth; and is associated with recurrence 
rate
[43]
STIM1 Hepatocellular carcinoma (HCC) HepG2, Hep3B,  
HCC‑LM3, and Huh7 cells
Enhances FA turnover; increases HCC migration [34]
Non‑small cell lung cancer A549 and H460 cells Knocks down STIM1; enhances the apoptosis induced by 
cisplatin
[40]
IP3R Estradiol‑induced breast cancer MCF‑7 cells Inhibits the growth of MCF‑7 cells via the IP3R inhibitor caf‑
feine
[63]
Glioblastoma cells blocks the glioblastoma invasion and migration via inhibiting 
the functions of IP3R
[71]
Colorectal cancer cell lines HCT116 and DLD‑1 cells IP3R isoform is remodeled by oncogenic k‑Ras; increases 
resistance to apoptosis
[72]
Colorectal carcinoma Increases resistance to apoptosis‑mediated Ca2+ signal 
between the endoplasmic reticulum and mitochondria
[78]
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cancer cells that partially substituted for functional 
ORAI1 channels [45]. Importantly, elevated expression 
level of the ORAI3 favored the association with ORAI1 to 
form heteromultimeric, store-independent, arachidonic, 
acid-regulated channels at the expense of “classical” 
homomultimeric ORAI1-based SOCE. The “nonclassi-
cal” association of ORAI3 and ORAI1 crippled the func-
tions of SOCE, leading to the resistance of malignant 
cells to apoptosis due to the declining infusion of Ca2+. 
Furthermore, the remodeled ORAI channels promoted 
cancer cell proliferation via activation of the transcrip-
tion factor nuclear factor of activated T cells (NFAT), fol-
lowed by the stimulation of cyclin D1 expression, which 
is a key rate-limiting controller of the G1/S phase tran-
sition. Faouzi et  al. [39] demonstrated that ORAI3 con-
tributed to the regulation of the cell cycle by the estrogen 
receptor expressed on breast cancer cells but not normal 
breast epithelial cells. These authors reported that knock-
down of ORAI3 caused a surprising increase in the levels 
of the well-established tumor suppressors P53 and P21, 
leading to cell cycle arrest.
STIM and ORAI have also been found to affect the 
migration of cancer cells. Increasing evidence has shown 
that tumor migration can be viewed as a Ca2+-depend-
ent signaling process, and STIM–ORAI is hijacked by 
malignant cancer cells to drive the biological functions 
required for tumor development [46]. In other words, 
although tumor migration is a complicated and multistep 
process, STIM–ORAI participates in almost every aspect 
of tumor cell migration, including the formation of lamel-
lipodia/membrane protrusions at the front edge, cycles of 
adhesion and detachment, cell body contraction, and tail 
retraction [47]. Blocking STIM-ORAI with its inhibitor, 
SKF-96365/2-aminoethoxydiphenyl borate (2-APB), or 
siRNA-mediated gene knockdown can obviously restrain 
the migration of hepatocarcinoma [34], breast cancer 
[37], glioblastoma multiforme [48], pancreatic adenocar-
cinoma [49], and melanoma cells [50]. The STIM-ORAI-
mediated Ca2+ influx accelerates focal adhesion (FA) 
turnover through the constitutively active forms of the 
small GTPase RAC1 and the Ca2+-dependent proline-
rich tyrosine kinase 2 (Pyk2) [51]. The efficiency of the 
assembly and disassembly of FAs decides the speed of 
cancer cell migration (Fig.  1c). Assembled FAs serve as 
anchorage points for actomyosin to provide the traction 
force that moves the cell body forward [52, 53]. At the 
same time, the STIM-mediated Ca2+ signaling enhances 
contractile forces by regulating the actomyosin reorgani-
zation. Actomyosin is a complex of actin filaments and 
non-muscle myosin II. The actomyosin generates corti-
cal tension with the extracellular matrix or neighboring 
cells and transmits the contraction to FAs that move the 
cell body [54]. These findings have corroborated that the 
STIM1-ORAI-mediated Ca2+ signaling exerted com-
prehensive and crucial functions to promote tumor cell 
migration by interacting with FA and actomyosin [55]. 
Moreover, knockdown of ORAI3 reduced the expres-
sion levels of cycle D and E1 and finally inhibited the 
transcriptional activity of NFAT [56]. NFAT is a consti-
tutively active form of the Ca2+-dependent transcription 
factor that plays a critical role in the tissue invasion of 
tumor cells by promoting the expression of autotaxin and 
cyclooxygenase 2 (COX2); these factors participate in the 
epithelial-to-mesenchymal transition [57].
The burgeoning field of IP3R in cancer biology
Growing attention has been paid to the special role of 
IP3Rs in tumorigenesis and tumor metastasis. Over the 
last 20 years, IP3Rs have been regarded as key regulators 
that control cell death and survival in a variety of cellular 
systems. Interfering with the amount of IP3R-mediated 
Ca2+ transport from the ER to the mitochondria deter-
mines the susceptibility of cells to apoptotic stimulation. 
Because IP3Rs can promote senescence and/or apopto-
sis, the available evidence indicates that down-regulating 
IP3Rs or dampening their activities can decrease cellu-
lar sensitivity to apoptotic signaling, finally resulting in 
the survival of cells with oncogenic features. An in vitro 
study showed that knockdown of IP3R1 prevented apop-
tosis in bladder cancer cells and rendered them resistant 
to chemotherapeutics [58]. Conversely, overexpression 
of IP3Rs might increase the sensitivity of cancer cells 
to cisplatin [59]. As the molecular bridge between the 
ER and mitochondria, IP3Rs are also hijacked by differ-
ent proto-oncogenes to give rise to cells with oncogenic 
features [60], such as Akt/protein kinase B (PKB) [61], 
Bcl-2 family members [62, 63], Bax inhibitor-1 (BI-1) [64, 
65], and K-ras-induced actin-interacting protein (KRAP) 
[66]. Recently, it has become clear that Bcl-2 directly 
targets the central modulation domain of IP3Rs through 
its tetrahydrobiopterin (BH4) domain to inhibit their 
functions [61]. The spatiotemporal interaction of BH4 
and IP3Rs hindered mitochondrial Ca2+ accumulation 
by abrogating Ca2+ transport from the ER to the outer 
mitochondrial membrane (Fig.  1d), therefore, the IP3R-
BH4 complex counteracted the pressure of pro-apoptotic 
proteins to protect tumor cells [67]. The Bcl-2 family was 
also shown to enhance basal Ca2+ leakage through sen-
sitization of IP3Rs to basal IP3 levels lower than the Ca2+ 
concentration in the ER [68, 69]. The low levels of Ca2+ 
in the ER destroyed the mitochondrial Ca2+ overload 
and decreased the susceptibility of the cells to apoptosis. 
Importantly, a peptide tool that was designed to disrupt 
the IP3R-BH4 complex could effectively induce an intra-
cellular Ca2+ overload and provoke cell death in diffuse 
large B cell lymphoma (DLBCL) cells [70]. However, 
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Kang et  al. [71] reported that the invasion and migra-
tion of tumor cells were suppressed by caffeine, which is 
a well-known inhibitor of IP3Rs. The expression levels of 
IP3R3 in colon cells were directly related to tumor aggres-
siveness [72]. These results suggest that the regulatory 
mechanisms of IP3Rs may vary in different types of can-
cer, and many mechanisms are not fully understood.
The interaction between STIM/ORAI and IP3Rs 
in cancer biology
The binding of IP3 to IP3Rs releases intracellular Ca2+, 
leading to a reduction in the Ca2+ concentration in the 
lumen of ER, which in turn activates the STIM sensor to 
allow extracellular Ca2+ to refill the empty ER Ca2+ stores 
across the ORAI in the plasma membrane. In rapidly 
growing cancers, IP3Rs are blocked by a variety of anti-
apoptosis proteins, resulting in Ca2+ overload in the ER. 
The harsh microenvironment perturbs the STIM-ORAI 
functions and induces the accumulation of misfolded 
proteins in the ER. This triggers an adaptation program 
referred to as “ER stress.” Chronic ER stress kills normal 
cells but can contribute to tumor cell dormancy, thereby 
permitting survival in the stressed environment until 
more favorable conditions are encountered. Overex-
pression of STIM could reverse ER stress, implying that 
Ca2+ overload restrains the STIM functions in cancer 
cells [73]. Oncogenic KRAS mutations could reduce the 
Ca2+ store content in the ER via promoting IP3R1 over-
expression to suppress agonist-induced Ca2+ release and 
mitochondrial Ca2+ accumulation in cancer cells [74]. 
Nevertheless, the relationships between STIM–ORAI 
and IP3Rs are not completely understood, and further 
investigations are needed to elucidate the mechanisms by 
which cancer cells control the functions of STIM-ORAI 
and IP3Rs.
STIM–ORAI and IP3Rs in cancer therapy
Multiple roles of STIM–ORAI and IP3Rs in several types 
of human cancer have made them attractive drug tar-
gets for tumor therapy. Inhibiting ORAI1 by pharmaco-
logic antagonists in cultured epithelial cells derived from 
ESCC patients impeded ESCC cell proliferation, invasion, 
and migration [75]. Importantly, the growth of ESCC 
in vivo was significantly suppressed when ORAI1-medi-
ated SOCE was knocked down by siRNA or blocked by 
pharmacologic inhibitors in xenografted nude mice. SKF-
96365 and 2-APB, which are inhibitors of store-operated 
Ca2+ entry, inhibited the growth and metastasis of tumor 
cells after 1  week of treatment [76, 77]. No increase in 
metastasis was observed in mouse cancer models [78], 
even 2  weeks after withdrawal of SKF-96365. Similar 
phenomena have been found in cervical and esophageal 
cancer mouse models.
To date, “proof of principle” studies of the Ca2+ signal 
channels have shown that STIM-ORAI and IP3Rs either 
do not differ or are overexpressed in tumor tissues com-
pared to those in normal tissues. However, the roles of 
STIM-ORAI and IP3Rs may be over- or underestimated 
depending on the use of the pharmacologic inhibitors or 
siRNA-mediated gene knockdown approaches in cancer 
cells. Moreover, only a relatively limited amount of infor-
mation concerning STIM-ORAI and IP3Rs is available to 
date due to their complicated and comprehensive func-
tions in tumor cells. Despite a wealth of data describing 
their functions, the elucidation of their roles in can-
cer is still at the beginning stages. How STIM-ORAI 
and IP3Rs affect carcinogenesis in  vivo, the relationship 
between these proteins and Ca2+ oscillations in cancer 
cells, and whether the participation of these proteins in 
the cancer procedure is a general mechanism need to be 
investigated.
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